These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

829 related articles for article (PubMed ID: 28174090)

  • 41. Larotrectinib in NTRK-Rearranged Solid Tumors
    Wilson FH; Herbst RS
    Biochemistry; 2019 Mar; 58(12):1555-1557. PubMed ID: 30865435
    [No Abstract]   [Full Text] [Related]  

  • 42. Identification of NTRK gene fusions in lung adenocarcinomas in the Chinese population.
    Zhao R; Yao F; Xiang C; Zhao J; Shang Z; Guo L; Ding W; Ma S; Yu A; Shao J; Zhu L; Han Y
    J Pathol Clin Res; 2021 Jul; 7(4):375-384. PubMed ID: 33768710
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neurotrophic tyrosine receptor kinase gene fusions in adult and pediatric patients with solid tumors: a clinicogenomic biobank and record linkage study of expression frequency and patient characteristics from Finland.
    Zhang W; Schmitz AA; Kallionpää RE; Perälä M; Pitkänen N; Tukiainen M; Alanne E; Jöhrens K; Schulze-Rath R; Farahmand B; Zong J
    Acta Oncol; 2024 Jul; 63():542-551. PubMed ID: 38967220
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers.
    Fuse MJ; Okada K; Oh-Hara T; Ogura H; Fujita N; Katayama R
    Mol Cancer Ther; 2017 Oct; 16(10):2130-2143. PubMed ID: 28751539
    [No Abstract]   [Full Text] [Related]  

  • 45. Detection of NTRK fusions in glioblastoma: fluorescent in situ hybridisation is more useful than pan-TRK immunohistochemistry as a screening tool prior to RNA sequencing.
    Bourhis A; Caumont C; Quintin-Roué I; Magro E; Dissaux G; Remoué A; Le Noac'h P; Douet-Guilbert N; Seizeur R; Tyulyandina A; Schick U; Merlio JP; Marcorelles P; Cappellen D; Uguen A
    Pathology; 2022 Feb; 54(1):55-62. PubMed ID: 34518039
    [TBL] [Abstract][Full Text] [Related]  

  • 46.
    Amatu A; Sartore-Bianchi A; Siena S
    ESMO Open; 2016; 1(2):e000023. PubMed ID: 27843590
    [TBL] [Abstract][Full Text] [Related]  

  • 47. NTRK fusions and Trk proteins: what are they and how to test for them.
    Weiss LM; Funari VA
    Hum Pathol; 2021 Jun; 112():59-69. PubMed ID: 33794242
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application.
    Yan W; Lakkaniga NR; Carlomagno F; Santoro M; McDonald NQ; Lv F; Gunaganti N; Frett B; Li HY
    J Med Chem; 2019 Feb; 62(4):1731-1760. PubMed ID: 30188734
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Acquired NF2 mutation confers resistance to TRK inhibition in an ex vivo LMNA::NTRK1-rearranged soft-tissue sarcoma cell model.
    Chen Y; Steiner S; Hagedorn C; Kollar S; Pliego-Mendieta A; Haberecker M; Plock J; Britschgi C; Planas-Paz L; Pauli C
    J Pathol; 2024 Jun; 263(2):257-269. PubMed ID: 38613194
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors.
    Rudzinski ER; Lockwood CM; Stohr BA; Vargas SO; Sheridan R; Black JO; Rajaram V; Laetsch TW; Davis JL
    Am J Surg Pathol; 2018 Jul; 42(7):927-935. PubMed ID: 29683818
    [TBL] [Abstract][Full Text] [Related]  

  • 51. TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations.
    Rosen EY; Goldman DA; Hechtman JF; Benayed R; Schram AM; Cocco E; Shifman S; Gong Y; Kundra R; Solomon JP; Bardelli A; Scaltriti M; Drilon A; Iasonos A; Taylor BS; Hyman DM
    Clin Cancer Res; 2020 Apr; 26(7):1624-1632. PubMed ID: 31871300
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Trk kinase inhibitors as new treatments for cancer and pain.
    Wang T; Yu D; Lamb ML
    Expert Opin Ther Pat; 2009 Mar; 19(3):305-19. PubMed ID: 19441906
    [TBL] [Abstract][Full Text] [Related]  

  • 53. NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma.
    Chiang S; Cotzia P; Hyman DM; Drilon A; Tap WD; Zhang L; Hechtman JF; Frosina D; Jungbluth AA; Murali R; Park KJ; Soslow RA; Oliva E; Iafrate AJ; Benayed R; Ladanyi M; Antonescu CR
    Am J Surg Pathol; 2018 Jun; 42(6):791-798. PubMed ID: 29553955
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Design, synthesis, and Structure-Activity Relationships (SAR) of 3-vinylindazole derivatives as new selective tropomyosin receptor kinases (Trk) inhibitors.
    Duan Y; Wang J; Zhu S; Tu ZC; Zhang Z; Chan S; Ding K
    Eur J Med Chem; 2020 Oct; 203():112552. PubMed ID: 32702585
    [TBL] [Abstract][Full Text] [Related]  

  • 55. NTRK Gene Fusion Detection in Atypical Spitz Tumors.
    Cappellesso R; Nozzoli F; Zito Marino F; Simi S; Castiglione F; De Giorgi V; Cota C; Senetta R; Scognamiglio G; Anniciello AM; Cesinaro AM; Mandalà M; Gianatti A; Valente MG; Valeri B; Sementa AR; Ricci C; Corti B; Roviello G; Dei Tos AP; Franco R; Massi D
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830218
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Entrectinib Induces Apoptosis and Inhibits the Epithelial-Mesenchymal Transition in Gastric Cancer with NTRK Overexpression.
    Sohn SH; Sul HJ; Kim BJ; Kim HS; Zang DY
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008821
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Activity of Entrectinib in a Patient With the First Reported
    Sigal D; Tartar M; Xavier M; Bao F; Foley P; Luo D; Christiansen J; Hornby Z; Maneval EC; Multani P
    J Natl Compr Canc Netw; 2017 Nov; 15(11):1317-1322. PubMed ID: 29118225
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation.
    Yan W; Zhang L; Lv F; Moccia M; Carlomagno F; Landry C; Santoro M; Gosselet F; Frett B; Li HY
    Eur J Med Chem; 2021 Apr; 216():113265. PubMed ID: 33652352
    [TBL] [Abstract][Full Text] [Related]  

  • 59. TRK Inhibition: A New Tumor-Agnostic Treatment Strategy.
    Kummar S; Lassen UN
    Target Oncol; 2018 Oct; 13(5):545-556. PubMed ID: 30276762
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Design and synthesis of a fluorinated quinazoline-based type-II Trk inhibitor as a scaffold for PET radiotracer development.
    Bernard-Gauthier V; Mahringer A; Vesnaver M; Fricker G; Schirrmacher R
    Bioorg Med Chem Lett; 2017 Jun; 27(12):2771-2775. PubMed ID: 28476569
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.